



















market  trends,  but  this  (me  in  the United  States.  For  this  reason,  I would  like  to  express my  sincere  gra(tude  to my  thesis 







The pharmaceu(cal  industry  is  facing a  lot of challenges recently,  like demographic changes,  the diﬃculty of  introducing new 
products to the market, new diseases complexity, the decreased R&D eﬃciency, the growth of the demands of the regulatory 
authori(es, and of course, the loss of the blockbuster's patent during the coming years. 
For  all  this  reasons,  this Master's  Thesis will  explain  the  common  trends  for  all  the pharmaceu(cal  companies  in  the United 
States, like the personalized medicine therapies, the focused expansion into emerging markets, the new growth models based in 
merges  and  acquisi(ons,  the  increasing  cost  of  the  health  services  over  the  country's  GDP  growth,  some  diﬀerent  ways  to 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Protec=ng  consumers  and  enhances  public  health  by  maximizing  compliance  of  FDA‐regulated 
products and minimizing risk associated with those products. 
Main Data 






















































































































The  Code  of  Federal  Regula=ons  (CFR)  collects  all  the  ﬁnal 
regula(ons published  in  the Federal Register. Sec(on 21   of 
the CFR contains most of  the  regula(ons pertaining  to  food 
and drugs.  
MANUAL OF POLICIES AND PROCEDURES (MaPPs) 
The  Manual  of  Policies  and  Procedures  (MaPPS)  provide 































don’t  require  preclinical  and  clinical  data  to  establish  safety  and  eﬀec(veness.  Instead,  generic  applicants must  scien(ﬁcally 
demonstrate that their product is bioequivalent.  

























provides  beneﬁts  to  elderly  people  or  nonelderly 
disabled people. 
Medicaid and CHIP 
Na=on’s  publicly  ﬁnanced  health  and  long‐term 











• People  aged under  65.They  become eligible  if  they  are  totally  and permanently  disabled  and have  received  Social  Security 





























































1  2  3  4  5  6  7  8  9  10  11  12  13  14 
Elderly  Nonelderly disabled 




























• Covers  impa(ent hospital  services,  short‐term care  in  skilled nursing  facili(es, post‐acute home health care 
and hospital care. 













































































































































































































• Nursing  facility  services  for  individuals  under 
age 21 
• Intermediate  care  facility  for  individuals  with 
mental retarda(on (ICF/MR) services 
• Home and community services (by waiver) 
• Inpa(ent  psychiatric  services  for  individuals 
under age 21 





















































































1  2  3  4  5  6  7  8  9  10  11  12 
BENEFICIARIES 
Employee  are  the  principal  source  of  health  insurance  in  the  United  States,  providing  health  beneﬁts  for  about  157 million 


































The  number  of  uninsured  has  increased  over  the  past  decade  and  jumped 
sharply  in  the past  year  largely due  to  the economic  recession and  resul(ng 
weak job market. Adults experienced a larger increase in their uninsured rate 
compared to children. This  is  largely due to more  limited eligibility for public 
coverage among adults.  
HOW DOES LACK OF INSURANCE AFFECT ACCESS TO HEALTH CARE? 
Health  insurance  makes  a  diﬀerence  in  whether  and  when  people  get 
necessary medical care, where they get their care, and ul(mately, how healthy 
people  are.  The  consequences  of  reduced  access  to  care  over  (me  can  be 











































































There will  be  a  new policy  that  covers  the  sickest  uninsured 
people.  The  government  will  chip  in  some  money  to  bring 
down the cost. 
SOLUTION 1.3 









Some  services will  become  free  in  all  new  private  insurance 
policies. For example, vaccina(ons in Medicare. 
SOLUTION 1.7 
The  life(me  limit  of  the  beneﬁts  of  some  health  insurance 
policies will disappear. 
SOLUTION 1.8 

















































































































































The aging of  the U.S. popula(on has been slowly occurring since mortality  rates began to decline  in  the early 1900s. Greater 
longevity meant that more Americans survived un(l their elder years, but high birth rates kept the youthful popula(on large as 














the  baby  boomers.  The  combina(on  of  the  baby  boomers  moving  through 
adulthood  and  the  low  birth  rates  of  subsequent  genera(ons  has  gradually 
pushed up the average age of the American popula(on.   
In 2011, the ﬁrst baby boomers (born 1946 – 1964) will reach the age of 65, and 
by 2030,  the youngest of  this group will have  reached  this milestone while  the 






Unskilled  paraprofessionals,  who  provide  the  bulk  of  long‐
term  care  services,  are  overwhelmingly  women  and 
dispropor(onately  drawn  from  racial  and  ethnic  minori(es.  
Low  wages  and  beneﬁts,  hard  working  condi(ons,  heavy 
workloads  and  a  job  that  has  been  s(gma(zed  by  society 
make worker recruitment and reten(on diﬃcult. 
While  a  short‐term  recession  could  temporarily  relieve  the 
worker  shortage,  the  gap  between  the  large  projected 
increase in demand for acute and long‐term care services and 









will be  the shit  from acute  to chronic  illnesses and  the  likely growing shortage of health care workers, especially nurses and 
paraprofessionals. 
The  ageing  popula(on  will  require  focusing  on  chronic 
diseases,  such  as  Alzheimer’s  Disease,  heart  disease,  and 
osteoporosis, rather than acute illnesses.  
• The  style  of  medicine  will  need  to  change  from  one‐(me 
interven(ons  that  correct  a  single  problem  to  the  ongoing 
management of mul(ple diseases and disabili(es. 
• With  chronic  illness  oten  comes  disability,  meaning  that 
long‐term care services, such as nursing homes, home health, 
personal  care,  adult  day  care,  and  congregate  housing,  will 
become much more important sources of care. 
• New  ways  will  need  to  be  found  to  integrate  medical  and 
long‐term care services, a  feat  that will be diﬃcult  in  the US 
because  of  the  fragmenta(on  of  the  ﬁnancing  and  delivery 
systems. 
SHIFT FROM ACUTE TO CHRONIC ILLNESS  HEALTH AND LONG‐TERM CARE WORKFORCE ISSUES 
Because  of  the  ageing 
r e g i s t e r e d  n u r s e 






































Alzheimer's  disease  is  the most  common  form  of  demen(a, 




Cancer  is  a  group  of  more  than  100  diseases  in  which 
abnormal  cells  grow  out  of  control,  thereby  invading  other 
parts  of  the  body.  There  were  more  than  1.5  million  new 
cases of cancer reported every year.  
CANCER  
Heart  disease—whether  it's  a  heart  aFack,  stroke,  cardiac 











































Sleep  disorders—whether  insomnia,  sleep  apnea,  or 








Incon(nence,  or  loss  of  bladder  control,  can  happen  for  a 
number  of  reasons.  Whether  it's  temporary  or  chronic,  it's 
unpleasant. It also can lead to emo(onal distress. 
INCONTINENCE 
About  a  third  of  Americans  between  the  ages  of  65  and  74 


















































The  research  of  a  new  drug  is  the  process  by  wich  poten(al  drugs  are  discovered  or 
designed.   
Modern biotechnology oten focuses on understanding the metabolic pathways related to a 
disease  state  or  pathogen,  and  manipula(ng  these  pathways  using  molecular  biology  or 
Biochemistry. 
The  process  of  drug  discovery  involves  the  iden(ﬁca(on  of  candidates,  synthesis, 
characteriza(on, screening, and assays for therapeu(c eﬃcacy. Once a compound has shown 
its value in these tests, it will begin the process of drug development prior to clinical trials. 
The  development  of  a  new  drug  refers  to  ac(vi(es  undertaken  ater  a  compound  is 
iden(ﬁed as a poten(al drug in order to establish its suitability as a medica(on. Objec(ves of 







An  innova(ve new drug  that  contains  a previously untried ac(ve  ingredient  can  take  years  to develop and  test. Ater  siting 
through a  large set of chemical compounds to ﬁnd one with the desired ac(on, a ﬁrm must test the drug using a formal and 
rigorous protocol so that  its safety and eﬃcacy can be determined with sta(s(cal validity. That  tes(ng can take much  longer 
than the laboratory research that produced the drug. With expenditures steadily accumula(ng at each stage, the research and  
development costs of developing a new drug can be high. Moreover, for every successful new drug, a ﬁrm will have had many 





























pharmacological  and  toxicological  analysis,  which  are  made  with  ethical  standards,  quality  and  research.  Once  approved 
successfully, con(nue to the clinical or research period in humans.   
PHASE I 











In  Phase  III  trials,  the  experimental  study  drug  or  tratment  is  given  to  large  groups  of  people  (1,000  –  3,000)  to  conﬁrm  its 






























































































































as  new  age  groups, 
genders, etc. 
• 20 to 80  • 200 to 300  • H u n d r e d s  t o thousands  • Thousands 
• Study of a single dose 












approved  Drug  X  vs. 
Standard  tratment 
for hypertension 
• Up to 1 month  • Several months  • Several years  • Ongoing  (following FDA approval) 



























sales  revenue.  This  is  because  successful  new  drugs  generate  large  cash  ﬂows  that  can  be 
invested in R&D  
A  recent, widely  circulated  es(mate put  the  average  cost  of  developing  an  innova(ve new 












































































































Early  leaders  in the ﬁeld of manufactured medicine  in the  late 1800s  included Squibb, Park‐Davis, Lilly, AbboF, and Upjohn & 
Searle. Other pioneers of the 19th century included Bayer, Pﬁzer and Johnson & Johnson. Merck was formed during World War I. 
Government Regula)on 















































































































































We  want  to  discover,  develop  and  successfully  market  innova=ve  products  to  prevent  and  cure 
diseases,  to ease suﬀering and to enhance the quality of  life.We also want to provide a shareholder 
return  that  reﬂects outstanding performance and  to adequately  reward  those who  invest  ideas and 
work in our company. 
Values 
Novar=s  is  commiged  to  equality  of  opportunity,  fairness,  work  and  lifestyle,  mutual  respect  and 






















We believe  that  to  be  successful  in  delivering  our  strategic  priori=es,  a  strong  focus  on  responsible 
business  is  essen=al.  It’s  fundamental  to our  reputa=on.  Stakeholders need  to be  conﬁdent  that we 











































































































































































































































for  diseases  like  hypertension,  diabetes,  an(‐allergic,  or  some  of  the 
nervous system disorder like depression, schizophrenia, etc.  
Nowadays, about one third of the pharma market by value is accounted for 































Indica(ons  Hypercholesterolemia  and mixed dyslipidemia  (Fredrickson  types  IIa  and  IIb)  to  reduce  total cholesterol. 
Other 
Nowadays,  Lipitor  is  the  top‐selling  branded  pharmaceu(cal  drug  in  the  world.  US  patent 
protec(on  is  scheduled  to  expire  in  June  2011.  However,  Pﬁzer  made  an  agreement  with 




















































Indica(ons  Rheumatoid  arthri(s,  psoria(c  arthri(s,  juvenile  idiopathic  arthri(s,  ankylosing  spondyli(s, chronic plaque psoriasis. 
Other 
Enbrel  is co‐marketed  in North America by Amgen and Pﬁzer  in  two separated  formula(ons, 
one in powder form, the other as a pre‐mixed liquid. The company Wyeth is the sole marketer 


















During  the 2005, Diovan was prescribed more  than 12 million (mes  in  the United  States. A 


















Inﬂiximab won  its  ini(al  approval  by  the  FDA  in  1998  for  the  treatment  of  Crohn’s  disease. 














Indica(ons  Metasta(c  Colorectal  Cancer,  Non‐Small  Cell  Lung  Cancer,  Metasta(c  Breast  Cancer, Glioblastoma, Metasta(c Kidney Cancer. 
Other 
Bevacizumab  received  its  ﬁrst  approval  in  2004  for  combina(on  use  with  standard 
chemotherapy  for  metasta(c  colon  cancer  and  non‐small  cell  lung  cancer.  In  2008,  it  was 
approved by the FDA for use in metasta(c breast cancer.  





















Based on  its safety and eﬀec(veness  in clinical  trials, Rituximab was approved by the FDA  in 














Indica(ons  Rheumatoid  arthri(s,  Polyar(cular  juvenile  idiopathic  arthri(s,  Psoria(c  arthri(s,  Ankylosing spondyli(s (AS) in adults, Crohn's disease, Plaque psoriasis. 
Other 
Adalimumab was constructed  from a  fully human monoclonal an(body and binds  the TNFα, 
preven(ng it from the ac(va(ng TNF receptors.  




















































India,  China,  Brazil,  Russia, Mexico‐‐all  so  alluring  in  a  world  in  which  countries  that  could  once  be  counted  on  for  steady 
increases are no longer delivering. 
So while drugmakers cut  jobs and otherwise  retrenched  in  the U.S. and Europe,  they con(nued  to  recruit emerging‐markets 
salespeople and draw up plans for R&D and manufacturing facili(es there. Novar(s and its $500 million plans for Russia, Novo 
Nordisk's $100 million  insulin plant  in  the same country, Sanoﬁ‐Aven(s' plans  for a plant  in Saudi Arabia, Eisai's bid  to move 
Aricept manufacturing to India for export worldwide, so drugmakers are bulking up in these new markets, literally. 
Novo Nordisk                     Russia                    
Novar(s          Russia & China                     
Sanoﬁ‐Aven(s              Saudi Arabia & China           
Elisai                         India                 
Merck                                       China & South Africa         
GlaxoSmithKline                           Argen(na, China & South Korea                 
Pﬁzer                                                                  Brazil     
AbboF                                                                          India                 































drugmaker  boasts  a  pipeline  of  branded  generic  pharmaceu(cal  products  covering  therapeu(c 
areas including cardiovascular, gastroenterology, metabolic and urology, as well as a manufacturing 
facility near Buenos Aires and an established primary care sales force. According to IMS Argen(na is 
the  eighth  largest  emerging  market,  valued  at  $3  billion  and  growing  at  a  rate  of  22  percent 














In  November  2009  Novar(s  forked  over  $125 million  for  85  percent  of  Chinese  vaccines  maker 
Zhejiang  Tianyuan.  But  that  investment  is  just  the  (p  of  the  iceberg.  Novar(s'  then‐CEO  Daniel 
Vasella announced his  inten(ons  to make China  the company's  third  largest market with a $1.25 
billion  investment  in  the  country.  (Vasella  has  since  been  replaced  by  Joe  Jiminez).Tianyuan  is  a 
privately‐owned vaccine company with a range of marketed and experimental products focused on 
















GlaxoSmithKline  snagged  marke(ng  rights  for  the  drug  in  China,  Brazil  and  India‐‐three  of  the 
largest  emerging  pharmaceu(cal  markets.  Addi(onally,  GSK  got  rights  to  sell  the  drug  in  South 
Korea  and  all  other markets where Amgen doesn't  have  a  commercial  presence.Amgen  and GSK 
also  agreed  to  share  commercializa(on  of  denosumab  in  Europe,  Australia,  New  Zealand  and 




















co‐promote  a  roster  of  GSK  primary‐care  products.The  Korean  pharmaceu(cal  market  has  been 
experience  impressive  pharma market  growth  (13.9%  CAGR  2006‐08),  and  was  the  13th  largest 
pharmaceu(cal market  in  the world  in 2008.  The market  is  expected  to  con(nue  its double‐digit 














The  fact  that  so many  companies  are  now merging,  reﬂects  the 
failure  of  each  company  to  discover  and  develop  its  own 
replacement pipeline.  
To  maintain  growth,  a  pharmaceu(cal  company  must  either 
produce  enough  new  products  to  replace  those  that  have  gone 
oﬀ‐patent or acquire rights to distribute drugs created by others. 
This  is  clearly  not  happening  on  a  large  enough  scale.  A  small 
number  of  patented  drugs,  each  with  annual  sales  of  $1  to  $5 
billion,  accounts  for  most  of  the  proﬁts  of  the  large 
pharmaceu(cal companies, and these proﬁts are vanishing as the 
patents  expire. Meanwhile,  the  number  of  new  drugs  approved 
for sale annually has steadily decreased over the past 15 years. 
Last year was  important for pharmaceu(cal mergers and acquisi(ons, with total deal values  in 2009 reaching almost $150bn. 
Driving  this  ac(vity  were  three  mega‐mergers  at  the  heart  of  the  industry,  as  Pﬁzer  took  over  Wyeth,  Roche  bought  the 
remaining shares in Genentech, and Merck & Co acquired Schering‐Plough.  
Those  historic  deals  signal  the  con(nued  importance  of  mergers  and  acquisi(ons  (M&A)  as  a  strategy  among  pharma 
companies,  with  associated  beneﬁts  and  challenges.  The  importance  of  consolida(on  and  alliances will  increase  from  2010 




































































































































Ater  two  years  topping  the  annual  layoﬀs  lists,  Pﬁzer  has  dropped  to  number  two  with  over 
10,000  fewer  job cuts announced during 2010.  It announced the  total 8,480  layoﬀs  in  rela(vely 
smaller batches: 1,080 in two January announcements, and 7,400 in separate May releases. 
Ater  merging  with Wyeth,  the  company  found  redundancies  as  it  accumulated Wyeth's  three 
dozen  sites  into  the  fold  with  its  previous  40.  Pﬁzer  found  places  to  cut  in  New  Jersey, 



































will  lose  their  jobs,  the  company  plans  to  create  another  2,500,  par(cularly  in  Asia.  Emerging 
markets has been a determining factor in many companies' layoﬀs as they search for new lines of 
revenue in an increasingly diﬃcult economy. For Bayer, it's the price of doing business, to ﬁnance 





Ater  purchasing  Solvay  Pharmaceu(cals,  AbboF  found  the  need  to  eliminate  3,000  jobs,  the 
largest layoﬀ in the company's history, with the majority of those hi}ng its European opera(ons. 























company  says  in  a  statement,  "with  the  pharmaceu(cal  industry  as  a  whole  facing  barriers  to 
technological innova(on that have halted progress in breakthrough novel drugs, stricter approval 
processes for new drugs in advanced na(ons, and radical upheaval in healthcare systems." 





















During  2009,  BMS  cut  out  7,000  employees.  The  company  con(nues  to  prepare  for  the  Plavix 
patent  cliﬀ,  as  generic  counterparts  take  over  a  larger  por(on of  the market.  BMS was  pos(ng 
higher‐than‐expected proﬁts when the layoﬀs occurred. But although the company's other drugs, 
including the an(psycho(c Abilify con(nue to do well, Plavix's $6.5 billion is hard to replace.  







help  people  get  beFer,  cause  adverse  side  eﬀects  that  outweigh  their  beneﬁts.  Even  though  these  products  are  tested, 
regulated, and approved by the Food and Drug Administra(on (FDA), many drugs have harmful side eﬀects. 
When pharmaceu(cal companies put a new drug on the market,  they have a responsibility to you, as the consumer,  to make 
sure  that what  they are  selling  is  safe.  If unforeseen problems develop while  the drug  is available  to  consumers,  these  same 
companies are  responsible  for aler(ng doctors and consumers  to  the problem. Unfortunately,  some unscrupulous  companies 
con(nue to market the drugs even ater serious health hazards and side eﬀects to you (and even death) have been reported. 
Some(mes drug companies don't recall certain drugs because they have a  lot  invested  in the drugs and even more money to 






























Approval  FDA. May 20, 1999. Generic name  Rofecoxib   
Claim 
About  50,000  people  have  sued  Merck  claiming  that  they  or  their  family  members  have  suﬀered 
medical problems such as heart aFacks or strokes ater taking Vioxx. In 2005, Merck was found liable 
in the ﬁrst case that went to trial and the plain(ﬀ was awarded $253.4 million in damages; however, 





























dosage,  intended  use,  eﬀects,  side  eﬀects,  route  of  administra(on,  risks, 




A  patent  is  granted  that  gives  the  company  that  developed  the  drug  an 
exclusive right to sell the drug as long as the patent is in eﬀect. As the patent 




do  not  allow  the  generic  drugs  to  look  exactly  like  the  brand‐name 















When  a  company  brings  a  new  drug  into  the  market,  the  ﬁrm  has 
already spent substan(al money on research, development, marke(ng 
and promo(on of the drug. 
Actually,  Generic  Drugs  are  cheaper  than  original  brand‐name 



































































































TEVA’s  sales  in  North  America  in  the  second  quarter  of  2010,  reached  roughly  $2,47B, 
accoun(ng  for  65%  of  total  sales  and  represen(ng  an  increase  of  17%  compared  with  the 




























Mylan  saw  revenues  during  the  ﬁrst  quarter  of  2010  rise  versus  the  same quarter  last  year 
($1.37 billion versus $1.27 billion). 
In 2007, Mylan acquired a controlling interest in India‐based Matrix Laboratories Limited, a top 
producer  of  ac(ve  pharmaceu(cal  ingredients  (APIs)  for  generic  drugs,  and  the  generics 
business of Germany‐based Merck KGaA. Through  these acquisi(ons, Mylan has grown  from 
the third largest generic and pharmaceu(cals company in the U.S. to the third largest generic 
and  specialty  pharmaceu(cals  company  in  the world. Mylan  now  has  approximately  15,000 





















Novar(s' generic unit Sandoz can  trace  its  roots back  to  the  late 19th century. The chemical 
company  Kern  &  Sandoz  was  set  up  in  Basel,  Switzerland,  by  Dr.  Alfred  Kern  and  Edouard 
Sandoz in 1886. Now the company has a worldwide presence, with U.S. headquarters based in 
Princeton,  NJ.  During  2010,  Don  DeGolyer  was  tapped  as  president  of  the  company's  U.S. 
opera(ons and head of commercial opera(ons for North America. 
Sandoz had a good second quarter during 2010, seeing net sales of approximately $2 billion. 
























Watson  Pharmaceu(cals  is  the  5th  largest  pharmaceu(cal  company  in  the  US  based  on 
number of prescrip(ons dispensed. Based  in Corona, CA, Watson's Generics division markets 
over  150  pharmaceu(cal  product  families,  including  one  of  the  largest  lines  of  oral 
contracep(ves  in  the  industry,  as  well  as  the  generic  version  of  the  popular  and  highly 
dispensed  opiate  narco(c  pain  medica(on,  Vicodin,  Hydrocodone  Bitartrate/APAP  tablets. 
Watson's Brand division markets over 20 pharmaceu(cal product  families,  including Ferrlecit 
for  the  treatment  of  iron  deﬁciency  anemia,  Rapaﬂo,  for  the  treatment  of  benign  prosta(c 
hyperplasia,  Gelnique,  the  only  gel  for  the  treatment  of  overac(ve  bladder,  Oxytrol,  a 





















Pharma  giant  Pﬁzer  has  been  turning  out  generics  for  a  while  through  its  Greenstone 
subsidiary.  Pﬁzer  got  Greenstone  through  its  April  2003  acquisi(on  of  Pharmacia,  and  the 
generics unit's opera(on began to increase the number of drugs it sold last year, when CEO Jeﬀ 
Kindler  formed  a  business  unit  headed  by  David  Simmons  with  its  own  budget  and 
management  focused  on  products  that  have  lost  patent  protec(on,  Bloomberg  notes. 
Greenstone manufactures and distributes generic versions of many Pﬁzer medicines, including 
several  injectables.  It  also  distributes  non‐Pﬁzer  medicines  through  agreements  with  other 
pharmaceu(cal companies such as India’s Aurobindo.   
The established products business unit porZolio contains more than 600 products spanning a 
























Du(ng  the  second quarter of 2010  ,  the  company  reported  total  revenues of $255.5 million 
and  income  from  con(nuing  opera(ons  of  $18  million,  or  $0.51  per  diluted  share.  These 
ﬁgures  compare  with  reported  revenues  of  $404  million  and  income  from  con(nuing 
opera(ons of $24 million, or $0.71 per diluted share, for the same period last year, according 
to a company statement. Par was hit by compe((on  to  its generic versions of AstraZeneca's 






















Laboratories.  The name  "Hospira"  is  derived  from  the words hospital,  spirit,  inspire  and  the 




in Lake Forest,  Illinois.  It has approximately 13,500 employees. Hospira  is  the world's  largest 
producer of generic injectable pharmaceu(cals and also manufactures generic acute‐care and 
oncology  injectables,  as  well  as  integrated  infusion  therapy  and  medica(on  management 
systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, 





















Privately  owned  Apotex  was  founded  in  1974,  and  is  the  largest  Canadian‐owned 



























Mallinckrodt  is  a  set  of  pharmaceu(cal,  chemical,  imaging,  and  respiratory  equipment 
suppliers  based  in  the  St.Louis, Missouri.  Founded  in  1867 when  the Mallinckrodt  brothers 
formed G. Mallinckrodt &  Company  to manufacture  pharmaceu(cal  chemicals, Mallinckrodt 
was  purchased  by  Tyco  Healthcare  (Tyco  Interna(onal)  in  2001. More  recently  in  2007,  the 
healthcare business units were spun oﬀ under the name Covidien. 
Mallinckrodt is the sole legal source for cocaine in the United States, which it receives from a 
Stephan Company plant  in Maywood, New Jersey and  is the only ﬁrm in the U.S.  licensed to 
import  coca  leaves.  Federal  restric(ons  also  bar  the  importa(on  of  drugs  such  as  Esterom 























become  India's  second  biggest  pharmaceu(cal  company.  The  company  has  over  190 





U.S.  Food  and  Drug  Administra(on  (FDA).  By  the  early  1990s,  the  expanded  scale  and 
proﬁtability from these unregulated markets enabled the company to begin focusing on ge}ng 


























the  1919  Treaty  of  Versailles,  followinf Germany’s  defeat,  Bayer was 
forced to give up Aspirin trademark and it lost its status as a registred 






where  the  trademark  is  owned,  where  the  trademark  is  owned  by 


















The  Congress  shall  have  power  to  lay  and  collect  taxes,  du=es,  imposts  and  excises,  to  pay  the  debts  and  provide  for  the 




















A  patent  is  a  property  right  granted  to  the  inventor  of  a  novel, 
nonobvious and useful  inven(on. Because the  inven(on must be novel 
(meaning  that  it  has  not  been  previously  disclosed  anywhere  in  the 
world) and because it cannot be obvious to one ordinarily skilled in the 








A  company may  apply  for  and  be  granted  a  patent  for  the 
drug,  or  the  process  of  producing  the  drug,  garan(ng 
exclusivity  rights  for  a  period  of  (me.  Government 
authori(es grant the permission for the company to market 
and  sell  the drug  ater  a  rigurous  study  and  tes(ng.  Patent 
protec(on  enables  the  owner  of  the  patent  to  recover  the 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The  patent  cliﬀ  is  quickly  approaching  and  big‐name  pharmaceu(cal 
manufacturers  face patent expira(on on  their  largest products. Nowadays, 
many  companies  are  lining  up  to  prepare  compe(ng  generic  versions  of 
once‐exclusive drugs. Starving abreast of expiring patents can put you at the 
forefront  of  investment  knowledge,  as  companies  enter  new  territories 















Lipitor  Plavix  Advair  Diovan  Seroquel 
Time is running out on the U.S. patents for many 
of the most popular brand‐name drugs. The next 





Facing  increased  compe((on  from  generics, 
drug  companies  are  busy  developing  new 
pipeline  drugs  and  devising  strategies  to  try  to 





At  the end of a patent’s  life,  the patent expires and  the  inventor no 
longer  has  any  rights  in  his  inven(on.    Thus,  anyone who wants  to 
make or sell that inven(on is now free to do so. Generally, when the 
patent  for  a  product  expires,  other  companies  will  begin  to  oﬀer 
compara(ve products at a lower price. The most common example of 
this is with pharmaceu(cal drugs.   Ater the patent on a name brand 
drug expires,  compe(tors will  begin  selling  a  generic  version of  that 
same drug,  because  the  original  pharmaceu(cal  company no  longer 
has  the  ability  to  protect  the  make‐up  of  its  brand  name  drug. 
example of  this  is with pharmaceu(cal drugs.   Ater the patent on a 
name  brand  drug  expires,  compe(tors  will  begin  selling  a  generic 


























During  the  last  years,  Pﬁzer 
h a v e  h a d ,  a t  l e a s t ,  9 
blockbuster  drugs  in  the 
market.  
A  blockbuster  drug  is  a  drug 
genera(ng more than $1 billion 
of  revenue  for  its  owner  each 
year. 
PFIZER’s DRUGS PATENT EXPIRY 2 















+7.3%  +8.3%  ‐3.0%  +20.9%   +17.3% 
Lipitor  Lyrica  Celebrex  Norvasc  Viagra  Xalatan  Detrol  Zyvox  Geodon/Zeldox Viagra  alata   Detr l  Zyv x  Geodon/
Zeldox 
rvasc Lipitor  Lyrica  C l r x 





















Pﬁzer's  blockbuster  cholesterol  pill  went  oﬀ 
patent in March 2010. Lipitor is the best‐selling 
drug  in  the  world,  with  nearly  $13  billion  in 
sales.  Pﬁzer  has  struck  a  deal  with  Ranbaxy 
Laboratories  that  will  enable  release  of  the 
generic  form outside  the United  States  before 





Developed  14‐years  ago,  it  is  the  most 
prescribed  eye drop  for  lowering  eye pressure 
in  glaucoma  pa(ents.  While  other  companies 
aFempted  to  capture  a  share  of  the  market 























































Eight  products  and  one  product 
line – Zyprexa, Cymbalta, Humalog, 
Alimta,  Cialis  Gemzar,  Evista  and 
Humulin, along with Animal Health 
– exceeded $1 B in 2009. Cymbalta 
became  the  second  product  in  Eli 
Lilly’s history to exceed $3 B. Alimta 



























































































Advair  Valtrex  Lamictal  Avandia  Filixo(de  Imigran 
PHARMACEUTICAL TURNOVER 
III. The Pharmaceu(cal Industry in the US 
During  the  last  years,  GSK  have 
had, at least, 6 blockbuster drugs 
in the market.  
A  blockbuster  drug  is  a  drug 
genera(ng  more  than  $1  billion 


























































































Diovan  Gleevec  Zometa  Femara  Sandosta(n  Lucen(s  Exelon 
NET SALES 1 
III. The Pharmaceu(cal Industry in the US 
During  the  last  years,  Novar(s 
h a v e  h a d ,  a t  l e a s t ,  7 
blockbuster  drugs  in  the 
market.  
A  blockbuster  drug  is  a  drug 
genera(ng more than $1 billion 





$1.511 B  $1.376 B  $1.291 B  $1.533 B  $1.033 B 
* Annual Sales 2010 







































































































+11.0%  ‐10.4%  +1.7%  ‐42.9% 
D u r i n g  t h e  l a s t  y e a r s , 
AstraZeneca have had,  at  least, 
10  blockbuster  drugs  in  the 
market.  
A  blockbuster  drug  is  a  drug 
genera(ng more than $1 billion 
of  revenue  for  its  owner  each 
year. 
ASTRAZENECA’s DRUGS PATENT EXPIRY 
Nexium  Seroquel  Crestol  Seloken/
Toprol‐XL 




$1.454 B  $1.287 B  $1.104 B  $618 B 
2015 
* Annual Sales 2009 








































































































Lantus  Lovenox  Plavix  Taxotere  Aprovel 
NET SALES OF SANOFI‐AVENTIS’ BEST SELLING PHARMACEUTICAL PRODUCTS 1 
III. The Pharmaceu(cal Industry in the US 
During  the  last  years,  Sanoﬁ‐
Aven(s    have  had,  at  least,  5 
blockbuster  drugs  in  the 
market.  
A  blockbuster  drug  is  a  drug 
genera(ng more than $1 billion 









LOVENOX*          12/02/2001          12/24/2004 
PLAVIX           02/12/2008          11/17/2011 
ALIMTA is protected by a compound patent. LANTUS          03/31/2009          12/02/2011 
TAXOTERE*          07/14/2007          05/14/2010 























































































professionals  thought  it  appropriate,  they  gave  that  informa(on  to  their  pa(ents.  However,  during  the  1980s,  some  drug 
companies started to give the general public more direct access to this informa(on through Direct‐to‐consumer ads. 
SOURCE: U.S. Department of Health & Human Services – FDA U.S. Food and Drug Administra(on 
In  the United States,  recent years have seen an  increase  in mass media adver(sements  for pharmaceu(cals. Expenditures on 
direct‐to‐consumer  adver(sing have more  than quintupled  in  the  seven  years  between 1997  and 2005,  from $700 million  in 
1997 to more than $4.2 billion in 2005   
The  mas s  marke(ng  to  consumers  o f 
pharmaceu(ca ls  i s  banned  in  over  30 
industrialized  countries.  Nowadays,  only  two 
countries allow Direct‐to‐consumer adver(sing of 
Prescrip(on  Drugs:  United  States  and  New 
Zealand.  Some  feel  it  is  beFer  to  leave  the 
decision  wholly  in  the  hands  of  medical 
professionals;  others  feel  that  consumer 
educa(on and par(cipa(on in health is useful, but 
consumers  need  independent,  compara(ve 
informa(on about drugs. For these reasons, most 
countries  impose  limits  on  pharmaceu(cal  mass 
marke(ng that are not placed on the marke(ng of 























to  ensure  that  companies  that  sell  prescrip(on  drugs  also  provide 
informa(on that is truthful, balanced and accurately described.  
CDER’s  Division  of  Drug,  Marke(ng,  Adver(sing  and  Communica(ons 
(DDMAC)  oversees  prescrip(on  drug  and  ac(vi(es.  DDMAC  does  this 
work by: 
• Looking  for  and  taking  ac(on  against  adver(sements  that  violate  the 
law. 
• Educa(ng industry and others about the speciﬁcs of the law. 















and  discuss  its  beneﬁts  and  risks.  However,  these  ads  must 
not be  false or misleading  in any way. All product  claim ads, 





Product  claim  ads  must  present  the  beneﬁts  and  risks  of  a 
prescrip(on drug in a balanced fashion. 
Print product claim also must include a brief summary about 
the  drug  that  generally  includes  all  the  risks  listed  in  its 
approved prescribing informa(on.  




Reminder  ads  give  the  name  of  a  drug,  but  not  the  drug's 
uses. These ads assume that the audience already knows the 
drug's  use.  A  reminder  ad  does  not  have  to  contain  risk 
informa(on about the drug because the ad does not say what 
the drug does or how well it works. Unlike product claim ads, 




Help‐seeking  ads  describe  a  disease or  condi(on but  do not 
recommend  or  suggest  a  speciﬁc  drug  treatment.  Some 
examples of diseases or condi(ons discussed  in help‐seeking 
ads  include  allergies,  asthma,  erec(le  dysfunc(on,  high 
cholesterol, and osteoporosis. The ads encourage people with 
these symptoms to talk to their doctor.  Help‐seeking ads may 












Product  claim  ads must  accurately  state  an  FDA‐approved  use 
for the drug. 




The  images used  in  the ads must  show man on  the age  range 
for users of the drug. 
As  required  by  the  Food  and  Drug  Amendments  Act  of  2007, 
print  ads must  include  the  statement  "You  are  encouraged  to 





























This  help‐seeking  ad  iden(ﬁes  seasonal  allergy 
symptoms  without  iden(fying  a  possible  drug 
treatment. 
Any  help‐seeking  ad  may  recommend  that  readers 
seek the advice of their healthcare provider. 







































have  tens of  thousands of  representa(ves around  the world. Sales  representa(ves called upon physicians  regularly, providing 
adver(sing and  free drug  samples.  This  is  s(ll  the approach  today; however, economic pressures on  the  industry are  causing 
pharmaceu(cal companies to rethink the tradi(onal sales process to physicians. 
Currently, there are approximately 81,000 pharmaceu(cal sales reps in the United States, or 1 for every 6.9 physicians. Because 


















































In  the context of  the diversiﬁca(on of  the porZolio of products and  services,  the R&D plays an  important  role. The  industry 














This  expansion  into  emerging  markets,  is  not  only  as  a  way  of 




this  emerging  countries  during  the  recent  years,  as  the  case  of 
India,  and  also  the  bureaucracy  and  the  problems  related  to 
intellectual property. In India, for example, regulators are trying to 
put  more  and  more  impediments  to  the  entry  of  large 
mul(na(onals.  All  these  companies  needs  to  establish 




This expansion  into emerging markets  is a way to  increase the 
sales force and an opportunity to carry out the R&D processes. 
The emerging markets will  play  an  important  role  in  the  future of  the pharmaceu(cal  sector.  It’s  expected  that  a  signiﬁcant 
propor(on  of  revenues  will  come  from  emerging  markets,  although  this  may  required  substan(al  ini(al  investments.  The 
pharmaceu(cal  companies  will  increase  the  percentage  of  ac(vi(es  that  develop  in  these  markets,  including  R  &  D.  This 
increase represents important changes in the business model.  
The companies prefer,  in order of  importance, China, Central Europe,  India, Eastern Europe and La(n America. The projected 
increase in the number of pa(ents with diseases such as cancer in these markets, make them very aFrac(ve. China is aFrac(ve 


























The  pharmaceu(cal  industry  is  subject  to  a  signiﬁcant  number  of  regula(ons.  In  the  United  States,  the  Food  and  Drug 




























The  real  problem  is  that  in most  countries  the  cost  of  health  service  is  growing  over  the  country’s GDP  growth  and wages. 
Furthermore, the trend is that this growth diﬀerence will be bigger in the coming years. 
Providers and funders of health services have not control over the aging popula(on, however, they can act in a beFer control of 
















This  implies  that  the  current  strategies  of  selling,  door  to  door  with  physicians,  will  not  be  suﬃcient  in  the  future.  The 
pharmaceu(cal industries should establish rela(onships with their pa(ents, providers and governments to provide services such 




beneﬁt  from  these  advances  will  expand.  On  the  other  hand,  the  industry  will  face  economic,  legal,  social  and  poli(cal 











decreased  R&D  eﬃciency  and  the  increase  of  the  demands  of  the  regulatory  authori(es  and  of  the  market  compe((on. 
Consequently,  pharmaceu(cal  companies  are  under  pressure  to  carry  out  an  eﬃcient  alloca(on  of  resources,  to  obtain 
maximum value from their products and adjust their accounts to the regulatory obliga(ons. 
At  the  same  (me,  funders  are  facing  major  challenges,  as  the  increasing  of  the  costs  because  of  demographic  changes  in 














In  recent  year,  there  have  been  two  signiﬁcant  demographic  changes.  On  one  hand,  it  has  been  a  signiﬁcant  aging  of  the 
popula(on due to the  increase of the  life expectancy. According to the US Census Bureau,  in 2030 the number of US ci(zens 
over 65 years will be approximately 20% of the popula(on.  
The  second major  demographic  shit  that  is  occurring  is  the  aging  of  the  workforce  in  the  health  sector,  which  leads  to  a 
signiﬁcant shortage of professionals.  
Also, several health problems appeared in rela(on to the current lifestyle, becoming less healthy in many developed countries. 
In  the US,  the obesity has been one of  the  factors  contribu(ng  to diabetes. According  to  the Center of Disease Control  and 
Preven(on, currently 23.6 million US ci(zens  (7.8% of  the current popula(on) have diabetes. Thus, global concern about  the 
alarming trends in morbidity, the loss of health from causes of illness and death. 
Mean data about worldwide morbidity according to the WHO: 
Cardiovascular diseases are the leading cause of death worldwide                   
Every year, nearly 10 M children under ﬁve die 
HIV / AIDS is the leading cause of adult mortality in Africa 
The aging of the popula(on contributes to increase the incidence of cancer and heart disease                     
Lung cancer is the cause of cancer deaths more common in the wor 
Pregnancy complica(ons cause about 15% of global deaths of women of childbearing age                     
Mental disorders such as depression are one of the 20 leading causes of disability 
Hearing loss, vision problems and mental disorders are the most common causes of disability                     
It’s expected that road traﬃc injuries come to occupy the ﬁth posi(on of death worldwide in 2030 







drugs  for  long‐term  chronic  diseases  (AIDS,  diabetes,  Alzheimer, 
etc.). Also cri(cized the lack of resources allocated to research into 
medicines  for  neglected  diseases  or  diseases  of  the  developing 
countries. 






In  the  pharmaceu(cal  ﬁeld,  responsibili(es  and  impact  of  industrial  ac(vity  beyond  the  research,  development  and 
commercializa(on of drugs. The posi(on of the Big Pharma companies requires the promo(on of health and welfare.  
Tradi(onally,  pharmaceu(cal  companies  have  enjoyed  the  sympathy  of  the  general  popula(on  because  their  products 
contribute to remedy health problems and quality of life for people and animals. However, in recent years, the pharmaceu(cal 




shareholders  is something that  is very present  in corporate statements and reports of pharmaceu(cal companies, companies 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